Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
40 hedge funds and large institutions have $34.1M invested in Sierra Oncology, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 44 → 40 (-4)
29% less capital invested
Capital invested by funds: $48M → $34.1M (-$13.9M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
+$193K |
| 2 |
Renaissance Technologies
New York
|
+$144K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$64.7K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$47.5K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$31.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.88M |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$923K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$107K |
| 4 |
Millennium Management
New York
|
-$91.8K |
| 5 |
PA
Perceptive Advisors
New York
|
-$61.9K |
SRRA Hedge Fund Activity: Q2 2017 in Review
40 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2017, worth a combined $34.1M — down 29% from $48M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SRRA and 4 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 5 added.
The largest buyer was New Leaf Venture Partners, adding an estimated $193K. The largest seller was Deerfield Management, cutting an estimated $1.88M.
- 40 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2017, down from 44 in Q1 2017.
- Funds reported $34.1M of Sierra Oncology, Inc. Common Stock stock for Q2 2017, down 29% quarter-over-quarter.
- 4 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2017 and 8 closed out, a net change of -4 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2017 was New Leaf Venture Partners, an estimated $193K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2017 was Deerfield Management, an estimated $1.88M sold.
Based on aggregated 13F filings for Q2 2017.